Finerenone
- TRADE NAME: Kerendia (Bayer)
- INDICATIONS: Reduction of the risk of hospitalization and mortality in patients with, for example, heart failure, chronic kidney disease.
- CLASS: Aldosterone antagonist / mineralocorticoid receptor antagonist (MRA)
- HALF-LIFE: 2–3 hours
FDA APPROVAL DATE: 07/09/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Amiodarone, CYP3A4 inducers, CYP3A4 inhibitors, Efavirenz, Erythromycin, Grapefruit Juice, Itraconazole
No available data in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
More frequent serum potassium monitoring is advised in patients receiving concomitant therapy with drugs or supplements that increase serum potassium.
Please login to see the rest of this drug profile
CARDIOVASCULAR.
ENDOCRINE/METABOLIC.
Page last updated 10/23/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
